Becton, Dickinson and Company (NYSE:BDX) Shares Sold by Arcadia Investment Management Corp MI

Arcadia Investment Management Corp MI decreased its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 22.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 29,011 shares of the medical instruments supplier's stock after selling 8,477 shares during the period. Becton, Dickinson and Company comprises 1.2% of Arcadia Investment Management Corp MI's portfolio, making the stock its 27th largest holding. Arcadia Investment Management Corp MI's holdings in Becton, Dickinson and Company were worth $6,645,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Flossbach Von Storch SE raised its position in shares of Becton, Dickinson and Company by 1.8% in the first quarter. Flossbach Von Storch SE now owns 194,130 shares of the medical instruments supplier's stock valued at $44,467,000 after buying an additional 3,493 shares during the last quarter. Personal CFO Solutions LLC increased its position in Becton, Dickinson and Company by 24.9% during the first quarter. Personal CFO Solutions LLC now owns 2,541 shares of the medical instruments supplier's stock worth $582,000 after purchasing an additional 507 shares during the last quarter. Stratos Wealth Partners LTD. increased its position in Becton, Dickinson and Company by 2.7% during the first quarter. Stratos Wealth Partners LTD. now owns 15,959 shares of the medical instruments supplier's stock worth $3,656,000 after purchasing an additional 418 shares during the last quarter. Davidson Investment Advisors increased its position in Becton, Dickinson and Company by 4.3% during the first quarter. Davidson Investment Advisors now owns 111,416 shares of the medical instruments supplier's stock worth $25,521,000 after purchasing an additional 4,630 shares during the last quarter. Finally, Beverly Hills Private Wealth LLC increased its position in Becton, Dickinson and Company by 10.6% during the first quarter. Beverly Hills Private Wealth LLC now owns 9,482 shares of the medical instruments supplier's stock worth $2,172,000 after purchasing an additional 912 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Bank of America lowered shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 price target for the company. in a research report on Thursday, May 1st. Wells Fargo & Company lowered shares of Becton, Dickinson and Company from an "overweight" rating to an "equal weight" rating in a research report on Thursday, May 1st. Wall Street Zen lowered shares of Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a research report on Friday, May 2nd. Morgan Stanley dropped their price objective on shares of Becton, Dickinson and Company from $280.00 to $196.00 and set an "overweight" rating for the company in a research report on Tuesday, May 6th. Finally, Stifel Nicolaus dropped their price objective on shares of Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Eight research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $219.22.

Becton, Dickinson and Company Stock Down 0.9%

Shares of BDX stock traded down $1.63 on Friday, hitting $175.87. The stock had a trading volume of 2,428,716 shares, compared to its average volume of 2,077,331. The firm has a market capitalization of $50.41 billion, a price-to-earnings ratio of 33.56, a P/E/G ratio of 1.33 and a beta of 0.25. The stock's 50 day moving average is $172.19 and its 200-day moving average is $206.41. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.64 and a current ratio of 1.13. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, topping analysts' consensus estimates of $3.28 by $0.07. The company had revenue of $5.27 billion for the quarter, compared to analysts' expectations of $5.35 billion. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The firm's revenue was up 4.5% compared to the same quarter last year. During the same period in the prior year, the company earned $3.17 earnings per share. As a group, research analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, June 30th. Shareholders of record on Monday, June 9th were issued a dividend of $1.04 per share. The ex-dividend date of this dividend was Monday, June 9th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.37%. Becton, Dickinson and Company's dividend payout ratio (DPR) is 79.39%.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP David Shan sold 1,166 shares of the firm's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $171.19, for a total transaction of $199,607.54. Following the transaction, the executive vice president owned 4,575 shares of the company's stock, valued at approximately $783,194.25. This trade represents a 20.31% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.36% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.